Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial.
BACKGROUND:Schistosomiasis affects millions of people, yet treatment options are limited. The antimalarial Synriam (piperaquine 150 mg/arterolane 750 mg) and the anthelminthic moxidectin revealed promising antischistosomal properties in preclinical or clinical studies. METHODOLOGY:We conducted two s...
Saved in:
Main Authors: | Beatrice Barda (Author), Jean T Coulibaly (Author), Maxim Puchkov (Author), Jörg Huwyler (Author), Jan Hattendorf (Author), Jennifer Keiser (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2016-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial.
by: Jennifer Keiser, et al.
Published: (2014) -
Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium.
by: Jean T Coulibaly, et al.
Published: (2012) -
Ultrasonographic evaluation of urinary tract morbidity in school-aged and preschool-aged children infected with Schistosoma haematobium and its evolution after praziquantel treatment: A randomized controlled trial.
by: Beatrice Barda, et al.
Published: (2017) -
Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.
by: Nada Abla, et al.
Published: (2017) -
Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial
by: Jean T Coulibaly, PhD, et al.
Published: (2017)